| 27.49 -0.01 (-0.04%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Silk Road Medical, Inc. operates as an American medical device company, focusing on innovative solutions for carotid artery disease. The firm's product portfolio is specifically engineered to support transcarotid artery revascularization (TCAR) procedures. Among its key offerings is the ENROUTE Transcarotid Neuroprotection System, designed to directly access the common carotid artery and initiate a temporary reversal of blood flow. The company also provides the ENROUTE Transcarotid Stent System, a distinctive stent characterized by its self-expanding and self-tapering capabilities. For streamlined initial entry to the common carotid artery, Silk Road Medical offers the ENHANCE Transcarotid Peripheral Access Kit. Additionally, the ENROUTE 0.014 Guidewire plays a crucial role in navigating and crossing target lesions, enabling the precise delivery of other interventional devices. Founded in 2007, Silk Road Medical, Inc. maintains its primary corporate offices in Sunnyvale, California.
Mon, 27 Jul 2026
Boston Scientific removes stroke prevention catheter after injury - MedTech Dive
Tue, 17 Sep 2024
Boston Scientific closes Silk Road Medical acquisition - MassDevice
Thu, 12 Sep 2024
Silk Road Medical (SILK) Surged After the Acquisition News - Yahoo Finance
Thu, 20 Jun 2024
Firm Advises Silk Road Medical on $1.26 Billion Acquisition by Boston Scientific - Wilson Sonsini
Wed, 19 Jun 2024
Boston Scientific to Buy Silk Road Medical for $1.26B - Twin Cities Business
Tue, 18 Jun 2024
Boston Scientific to Buy Silk Road Medical for About $1.26 Billion - WSJ
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|